HC Wainwright Issues Negative Estimate for ACAD Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research report issued on Thursday, February 26th. HC Wainwright analyst A. Ghosh now anticipates that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter, down from their prior estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q2 2026 earnings at $0.08 EPS, FY2026 earnings at $0.46 EPS, FY2027 earnings at $1.71 EPS, FY2028 earnings at $2.78 EPS, FY2029 earnings at $3.11 EPS and FY2030 earnings at $3.25 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $1.48. ACADIA Pharmaceuticals had a return on equity of 12.49% and a net margin of 36.49%.The business had revenue of $298.00 million during the quarter, compared to the consensus estimate of $292.54 million. During the same period in the previous year, the company posted $0.86 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis.

A number of other equities analysts have also commented on the stock. Stifel Nicolaus lowered their price target on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating on the stock in a research report on Thursday, February 26th. Piper Sandler set a $37.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, December 16th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research report on Monday, December 29th. Citigroup increased their price target on ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, Royal Bank Of Canada dropped their price objective on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.05.

ACADIA Pharmaceuticals Stock Performance

ACAD opened at $22.50 on Monday. The stock has a fifty day moving average of $25.32 and a 200-day moving average of $24.40. The company has a market capitalization of $3.84 billion, a P/E ratio of 9.83, a P/E/G ratio of 18.95 and a beta of 0.66. ACADIA Pharmaceuticals has a fifty-two week low of $13.40 and a fifty-two week high of $28.35.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC boosted its stake in shares of ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 386 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $26,000. Geneos Wealth Management Inc. increased its holdings in ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 756 shares in the last quarter. Smartleaf Asset Management LLC raised its position in ACADIA Pharmaceuticals by 107.0% in the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 885 shares during the last quarter. Finally, Transamerica Financial Advisors LLC raised its position in ACADIA Pharmaceuticals by 304.5% in the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 1,005 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Insider Activity

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the transaction, the executive vice president owned 7,609 shares of the company’s stock, valued at approximately $177,898.42. The trade was a 47.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.30% of the company’s stock.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Wolfe Research initiated coverage with an Outperform rating and a $33 price target, highlighting conviction-driven opportunities across ACADIA’s neuroscience franchises — a near-term catalyst for investor optimism. Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) Therapeutic Domains
• Positive Sentiment: ACADIA appointed Jonathan M. Poole to its board (joining the Audit Committee). His biotech finance and corporate leadership experience may strengthen governance and investor confidence. Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
• Neutral Sentiment: ACADIA announced it will request CHMP re-examination after a negative CHMP opinion on trofinetide for Rett syndrome — a standard regulatory next step that preserves the chance of approval but leaves near-term uncertainty. Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
• Neutral Sentiment: Some outlets report an average analyst rating of “Moderate Buy” for ACAD, reflecting mixed but generally constructive sell‑side sentiment; these consensus views can limit downside but aren’t immediate catalysts. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of “Moderate Buy” by Analysts
• Neutral Sentiment: Reported short‑interest entries appear to show zero shares / NaN changes (data glitch); there’s no clear short‑squeeze signal from these reports — treat short‑interest data as unreliable until corrected.
• Negative Sentiment: European regulators (CHMP/EMA) recommended against approval of trofinetide for Rett syndrome, which is a clear near‑term negative: it reduces the likelihood of European revenue for the drug absent a successful re‑examination. European Regulators Recommend Against Acadia’s Application for Rett Syndrome Treatment
• Negative Sentiment: HC Wainwright published a pessimistic near‑term outlook for ACAD’s Q1 earnings, which can amplify selling pressure if investors fear guidance misses or margin risk. HC Wainwright Has Pessimistic Outlook of ACAD Q1 Earnings

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.